Figure 4.
LC-MS-MS-based glycoproteomics comparing plasma glycopeptides in patients before and after they contracted COVID-19, (A) waterfall plot showing variation in median fold change of each glycopeptide on log2 scale from all patients, (B) heatmap of 34 glycopeptides (p≤0·050) in patients, (C) box plots showing variation in two representative glycopeptides of haptoglobin and β-2-glycoprotein 1 and (D) variation in two representative glycopeptides of haptoglobin and β-2-glycoprotein 1 across different patient groups
B is colour coded for WHO OSCI scores; protein names with site of glycosylation are given for each glycopeptide and identical names refer to different glycan chains at the same site of glycosylation. LC-MS-MS=liquid chromatography-tandem mass spectrometry. Hex=Hexose. NAc=N-acetylhexosamine. Neu5Ac=N-acetylneuraminic acid. Fuc=Fucose. OSCI=ordinal scale of clinical improvement. *Adjusted p≤0·05. †Adjusted p≤0·01. ‡Adjusted p≤0·001.